A new study conducted by researchers at the University of Waterloo analyzed data from nearly 500,000 Canadian patients who lived in nursing homes across Canada between 2000 and 2022. It found… read more.
Intra-Cellular Therapies, Inc. announced positive results from Study 304 evaluating the efficacy and safety of lumateperone 42 mg for the prevention of relapse in adult patients with schizophrenia…. read more.
Bristol Myers Squibb announced that new clinical and health economics and outcomes research data (HEOR) from its neuropsychiatry portfolio evaluating obenfy (xanomeline and trospium chloride) in schizophrenia in… read more.
Bristol Myers Squibb announced that the FDA has approved Cobenfy (xanomeline and trospium chloride), an oral medication for the treatment of schizophrenia in adults. Cobenfy represents the first… read more.
Indivior has discontinued sales and marketing for its schizophrenia drug Perseris. This last decision, prompted by increased payor management impacts, is expected to make the product financially unviable… read more.
Laboratorios Farmacéuticos Rovi, S.A. has announced that the FDA has authorised the marketing of Risvan (risperidone ISM ) for the treatment of schizophrenia in adults. Risperidone ISM is… read more.
Young men with cannabis (marijuana) use disorder have an increased risk of developing schizophrenia, according to a study led by researchers at the Mental Health Services in the… read more.
People with severe mental illness are less likely to attend cancer screening compared to those who do not have such conditions, according to new research from the University… read more.
AbbVie announced that it has submitted a supplemental New Drug Application (sNDA) for cariprazine (Vraylar) to the FDA for the adjunctive treatment of major depressive disorder (MDD) in… read more.
Ketamine is effective for the acute treatment of severe suicidal ideation, researchers reported on February 2, 2022 in The BMJ/British Medical Journal. “This study confirmed in a large… read more.
New research published in the Proceedings of the National Academy of Sciences shows that examining genetic mutations in individuals with severe schizophrenia can improve the ability to detect disease-associated rare… read more.
The Janssen Pharmaceutical Companies of Johnson & Johnson has announced the FDA has approved long-acting atypical antipsychotic Invega Hafyera (6-month paliperidone palmitate), the first-and-only twice-yearly injectable for the… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
